AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Crestor RAPID (The Efficacy of RosuvAstatin for Korean Dyslipidemia PatIents With Diabetes)
Completed
- Conditions
- DyslipidemiaDiabetes
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2010-03-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5000
- Registration Number
- NCT00526552
- Locations
- 🇰🇷
Research Site, Seoul, Songpa-gu, Korea, Republic of
Real-life EValuation Of High Dose RosUvastatin in High Risk Patients After TitraTION
Completed
- Conditions
- Hypercholesterolemia
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2012-03-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1482
- Registration Number
- NCT00526721
- Locations
- 🇰🇷
Research Site, Seoul, Songpa-gu, Korea, Republic of
COmpliance and Efficacy in Mono and Combination Tablet Study ATacand/Atacand Plus
Completed
- Conditions
- Hypertension
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2010-12-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 9000
- Registration Number
- NCT00526279
- Locations
- 🇰🇷
Research Site, Seoul, Songpa-gu, Korea, Republic of
12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe
Phase 3
Completed
- Conditions
- HypercholesterolemiaCoronary Heart DiseaseAtherosclerosis
- First Posted Date
- 2007-09-06
- Last Posted Date
- 2011-05-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1743
- Registration Number
- NCT00525824
- Locations
- 🇻🇪
Research Site, Brentwood, Venezuela
Epidemiological Study to Assess the Symptoms and Patterns of Diagnosis and Treatment of GERD
Completed
- Conditions
- GERD
- First Posted Date
- 2007-09-03
- Last Posted Date
- 2009-07-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2717
- Registration Number
- NCT00524355
- Locations
- 🇻🇳
Research Site, Ho Chi Minh City, Vietnam
Asthma Control-A "Patient Follow up Programme" Maintenance and Reliever Therapy in a Single Inhaler
Completed
- Conditions
- Asthma
- First Posted Date
- 2007-09-03
- Last Posted Date
- 2009-07-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1254
- Registration Number
- NCT00524641
- Locations
- 🇻🇳
Research Site, Ho Chi Minh City, Vietnam
InPractice Survey on the Treatment of Hypercholesterolemia
Completed
- Conditions
- Hypercholesterolemia
- First Posted Date
- 2007-09-03
- Last Posted Date
- 2011-02-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2500
- Registration Number
- NCT00523796
- Locations
- 🇻🇳
Research Site, Hanoi, Vietnam
Esomeprazole And Symptomatic Response In Patients With Or Without An Elevated Risk For Non-Steroidal Anti-Inflammatory Drug (NSAID)-Associated GI Damage
Completed
- Conditions
- Heartburn
- First Posted Date
- 2007-09-03
- Last Posted Date
- 2008-09-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1220
- Registration Number
- NCT00524329
The Effect of Lifestyle-Adjustments Prior to Medical Treatment on the Effect of Medical Treatment in Reflux Patients
Completed
- Conditions
- GERDQuality of Life
- First Posted Date
- 2007-09-03
- Last Posted Date
- 2008-09-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 990
- Registration Number
- NCT00524251
- Locations
- 🇳🇱
Research Site, Zoetermeer, Netherlands
Symbicort SMART (Symbicort Maintenance And Reliever Therapy)
Completed
- Conditions
- Asthma
- First Posted Date
- 2007-08-31
- Last Posted Date
- 2009-07-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2000
- Registration Number
- NCT00523679
- Locations
- 🇰🇷
Research Site, Seoul, Songpa-gu, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath